Overexpression of HER2 and HER3 has been reported in a variety of solid tumours, including CRC, and as such, these receptors are ideal targets for therapy with monoclonal antibodies, small-molecule TKIs in combination with chemotherapeutic interventions. The gene discussed is ERBB2; the disease is colorectal carcinoma.